GlassScriptPhysician profile
William A Shapse
NPI 1801880836
$4,264.71
in general payments reported to CMS, 2019-2025
22 companies · $680 in 2025
The $680 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $267 · 2021: $572 · 2022: $845 · 2023: $560 · 2024: $805 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,001 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,000.50 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,206.24 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,072.76 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $643.60 | 2019-2025 | Zepbound, Mounjaro |
| Amgen INC. | $291.44 | 2019-2024 | Repatha, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.39 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $177.93 | 2019-2021 | |
| Abbott Laboratories | $99.90 | 2021-2022 | |
| Pfizer INC. | $97.19 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $83.31 | 2019-2022 | |
| Amarin Pharma, INC. | $66.51 | 2019-2021 | |
| Insulet Corporation | $46.48 | 2021-2023 | Omnipod |
| Dexcom, INC. | $39.08 | 2021-2025 | Dexcom G6 Transmitter |
| Philips North America LLC | $32.67 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Merck Sharp & Dohme LLC | $30.19 | 2020-2025 | Capvaxive, Gardasil 9 |
| Recordati_rare_diseases_inc. | $27.55 | 2025 | Isturisa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $24.97 | 2019 | |
| Boston Scientific Corporation | $22.73 | 2020 | |
| Exact Sciences Corporation | $19.47 | 2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $18.84 | 2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $18.30 | 2019 | |
| Corcept Therapeutics | $16.75 | 2023 | Korlym |
| Cardiovascular Systems INC. | $15.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Shapse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.